Diaceutics PLC Presentation at Big Data Belfast
24 October 2019 - 5:01PM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
24 October 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Presentation at Big Data Belfast
Diaceutics PLC (AIM: DXRX), the data analytics and
implementation services company which services the global
pharmaceutical industry, announces that it will attend the Big Data
Belfast conference as an invited speaker at the ICC Waterfront in
Belfast on 24 October. Big Data Belfast is one of the leading data
and technology events on the island of Ireland, driving thought
leadership in one of the most exciting and expansive business
clusters. This established conference has been running for seven
years, featuring global data and analytics experts and best in
class data driven organisations.
Derek Hosty, Head of Global Data at Diaceutics will deliver a
presentation during the Artificial Intelligence and Machine
Learning section of the conference entitled 'Using Big Data to make
Better Decisions in Healthcare.' The presentation will be available
on the Company's website from the end of the day and can be
accessed via this link:
https://www.diaceutics.com/using-big-data-to-make-better-decisions-in-healthcare/
The Company's proprietary data offering combines diagnostic
testing, claims and prescription data providing actionable insights
for 115m+ patient records covering 47 deductive pathways in 35
global markets. Diaceutics' presentation will demonstrate how smart
application of the Company's data analytics can significantly
impact outcomes for patients in need of precision medicine
therapies using a case study of metastatic lung cancer.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and
implementation services provider for global pharmaceutical
companies. The Company, quoted on the Alternative Investment Market
(AIM) of the London Stock Exchange, is enabling Pharma to
accelerate their market penetration and achieve a better return on
precision medicine therapies by helping them to revolutionise
patient testing. By generating insights from its data lake of
clinical laboratory testing data and other data, Diaceutics helps
Pharma understand and leverage the diagnostic landscape through
initiatives that improve patient testing, leading to better
treatment outcomes. The Company works with more than 30 global
pharmaceutical companies across hundreds of precision medicine
projects. The Company employs a leading global group of experts
from the laboratory, diagnostic and pharmaceutical industries.
www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABUBDGRBDBGCX
(END) Dow Jones Newswires
October 24, 2019 02:01 ET (06:01 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024